Personalized pre-surgery treatment for HER2-positive breast cancer
Part of Cancer clinical trials.
This trial tests a personalized treatment plan for HER2-positive breast cancer before surgery. The treatment is adjusted based on how your cancer responds, aiming to give you the best possible outcome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II or III breast cancer (cancer has spread to nearby lymph nodes but not to other parts of the body).
- Your cancer is HER2-positive (a protein that makes cancer grow faster).
- You are between 18 and 70 years old.
- Your heart is working well enough (LVEF of 55% or more) and you have no serious heart problems.
- Your blood counts and organ function are within normal limits (kidney, liver, and blood cell counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted drugs (Initumab and Pyrrotinib) plus chemotherapy before surgery for HER2-positive breast cancer. It compares different treatment lengths to see which is more effective and safe.
This Phase 2 trial compares nab-PH plus pyrrolitinib versus TCbHP as treatment given before breast surgery. It aims to see which option works better and is safe for people with HER2-positive invasive breast cancer.
This study tests two ways to treat HER2-positive breast cancer before surgery: one uses a single drug (SHR-A1811), and the other uses that drug followed by a combination (THPy). The goal is to see which approach works better at shrinking tumors before surgery.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
This trial tests a combination of two targeted drugs (SHR-A1811 and pertuzumab) given before surgery to shrink HER2-positive breast cancer. It aims to see if this approach improves outcomes for patients with early-stage but high-risk disease.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.